Morphine / hydromorphone / oxycodone / heroin and tramadol
https://dxm-atlas.org/en/compare/morphine-vs-tramadol/
Two separate pairs are shown: DXM + A and DXM + B. Assessing DXM + A + B falls outside the scope of this comparison.
Comparison sections
Overlapping ranges: the ordering by hazard level remains uncertain
PHI and scope
Conditions and group scope
A
B
Mechanisms
A
B
What could go wrong?
A
B
How well is this understood?
A
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: low
Confidence in direct human evidence involving DXM: low
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodB
Mechanism confidence: high
Confidence in the mechanism: high
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodConfidence in human DXM data: medium
Confidence in direct human evidence involving DXM: medium
M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.
MethodUnder which conditions was it studied?
A
B
Main limitations
This field lists specific limitations of the evidence described for each entry. “—” means no separate text is shown here; qualifications in the entry’s explanation still apply.
A
B
Sources
Similarities and differences
Effects involved
Only A: SED — Sedation
Shared: OP — μ-opioid effects
Only B: SERT — Serotonin reuptake · SEIZ — An additional seizure-related concern
Mechanism groups
Shared: Sedation and respiration
Only B: Serotonin-related · Seizure-related concern
Potential problems
Only A: Aspiration
Only B: Seizures
Study conditions
Only A: Laboratory testing outside the body
Only B: Medicine prescribing information
Conclusion
Experiments with human transporters show substantial differences between opioids. Tramadol, pethidine, and methadone have serotonergic mechanisms, whereas morphine and hydromorphone did not demonstrate analogous SERT inhibition in the studied system. Fentanyl has a separate clinical serotonergic signal without the same transporter inhibition. Tapentadol inhibited SERT at potentially clinically relevant concentrations and was the most potent NET inhibitor among the tested opioids. The transporter mechanism is well supported; uncertainty concerns the clinical severity of the DXM pair, so its M confidence is High and D remains Low [5].
Limitations
With nonserotonergic opioids, the principal concerns are breathing and consciousness. The assessment rests on pharmacological mechanisms; the extent of their amplification with DXM remains uncertain. There is no basis for relying on DXM to protect against opioid toxicity.